Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

BACKGROUND: Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), has been shown to increase the efficacy of endocrine therapies in hormone receptor (HR)-positive metastatic breast cancer. However, because breast cancer is a highly heterogeneous disease, the responses of different patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Cancer
Hauptverfasser: Yi, Zongbi, Ma, Fei, Liu, Binliang, Guan, Xiuwen, Li, Lixi, Li, Chunxiao, Qian, Haili, Xu, Binghe
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2019
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6515626/
https://ncbi.nlm.nih.gov/pubmed/31088410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5668-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge